Insight takes a look at the innovations, breakthroughs, setbacks, events and stories that shaped the Australian ophthalmic sector in 2020. Read more
The pandemic prompted a rethink of the way Orthoptics Australia delivered its events. The unexpected advantages mean some online components will be here to stay, writes President JANE SCHULLER. Read more
The skill to decentre a lens saves both time and money and can be the defining service that separates the practice from the rest of the pack. ROWAN SMITH details the calculations involved. Read more
As the current economic climate prompts optometrists to reconsider practice valuations, exit plans and buyer interest, RHIANNON BOWMAN reflects on where opportunities lie for the next generation of independent practice owners. Read more
A multitude of studies both on self-esteem and myopia control show kids as young as eight can manage contact lenses safely and competently. Insight speaks with eyecare practitioners and academics about treating this younger age group. Read more
Medicinal cannabis is often presented as an alternative treatment for glaucoma. Although there is evidence that cannabis lowers intraocular pressure, its role as a viable glaucoma therapy is limited by a short duration of action, psychotropic effects, and possible tachyphylaxis.
Opening a greenfield practice during a pandemic in Australia’s hardest-hit city has thrown up its challenges, especially when it comes to purchasing big ticket items. But DR JAYSON STONE found a way thanks to the efforts of a major supplier.
The breadth of choice in lens coatings and treatments plays to the patient’s advantage, whether they are motivated by function, fashion – or both. Insight talks shop with lens manufacturers and dispensers about market trends and retail dynamics. Read more
Choosing the frame product range can be both an exciting and stressful prospect for any independent practice. It also says a lot about a business, so it’s important to get right, writes EMMA ROBERTS. Read more
In the space of 23 years AFT Pharmaceuticals has gone from a home-based business to a multinational company. Its eyecare business is also experiencing remarkable growth, and more therapies are in the pipeline, including one for glaucoma.